IL6 and breast carcinoma: For example, elevated levels of IL-6 stimulate hyperactivation of JAK/STAT3 signaling, which is often associated with poor patient outcomes in colorectal cancer (32), breast cancer (33), oral cancer (34), and myeloma (35).